Cargando…

4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma

Detalles Bibliográficos
Autores principales:	Woroniecka, Karolina, Fecci, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343573/ https://www.ncbi.nlm.nih.gov/pubmed/32676514 http://dx.doi.org/10.18632/oncoscience.505

Ejemplares similares

T-cell exhaustion in glioblastoma
por: Woroniecka, Karolina, et al.
Publicado: (2018)

Checkpoint blockade therapy for functioning pituitary adenomas
por: Lorrey, Selena J., et al.
Publicado: (2020)

Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
por: Salek-Ardakani, Shahram, et al.
Publicado: (2023)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)

SYST-05 BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS
por: Lorrey, Selena, et al.
Publicado: (2023)

4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation
por: Qu, Qiu-xia, et al.
Publicado: (2020)

HSP90 as an emerging barrier to immune checkpoint blockade therapy
por: Tang, Daolin, et al.
Publicado: (2022)

Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
por: Tsuji, Ai, et al.
Publicado: (2023)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
por: Tomaszewski, William H., et al.
Publicado: (2022)

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
por: van der Sluis, Tetje C., et al.
Publicado: (2023)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
por: Arrieta, Víctor A., et al.
Publicado: (2023)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

BSCI-03. T CELL EXHAUSTION SIGNATURES VARY BY TUMOR TYPE AND ARE INDEPENDENT OF INTRACRANIAL LOCATION
por: Woroniecka, Karolina, et al.
Publicado: (2019)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model
por: Bausart, Mathilde, et al.
Publicado: (2022)

Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities
por: Kaviani, Elina, et al.
Publicado: (2022)

Activation of 4-1BBL(+) B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
por: Lee-Chang, Catalina, et al.
Publicado: (2020)

Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
por: Liu, Ying L., et al.
Publicado: (2018)

The Legislative Approach and System Improvement of China’s Compulsory Licensing for Drug Patents
por: Cao, Zhang, et al.
Publicado: (2021)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
por: Fane, Lauren S., et al.
Publicado: (2022)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
por: Zhou, Binghan, et al.
Publicado: (2021)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
por: Laspidea, Virginia, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

BSCI-07. BONE MARROW T-CELL SEQUESTRATION IN THE SETTING OF BRAIN METASTASES
por: Chongsathidkiet, Pakawat, et al.
Publicado: (2019)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l5fo0dn21djhkbj1lcv20st2n4